Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
1,148.84
-6.13 (-0.53%)
At close: Jul 31, 2026, 4:00 PM EDT
1,147.63
-1.21 (-0.11%)
After-hours: Jul 31, 2026, 7:59 PM EDT
Eli Lilly Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 72,250 | 65,179 | 45,043 | 34,124 | 28,541 | 28,318 |
Revenue Growth | 47.44% | 44.70% | 32.00% | 19.56% | 0.79% | 15.40% |
Gross Profit Gross Profit Growth | 59,845 | 54,127 | 36,625 | 27,042 | 21,912 | 21,006 |
Operating Income Operating Income Growth | 31,522 | 26,302 | 12,899 | 6,457 | 7,127 | 6,357 |
Net Income Net Income Growth | 25,277 | 20,640 | 10,590 | 5,240 | 6,245 | 5,582 |
Earnings Per Share EPS Growth | 28.15 | 22.95 | 11.71 | 5.80 | 6.90 | 6.12 |
EPS Growth | 129.05% | 95.99% | 101.90% | -15.94% | 12.75% | -9.87% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Baqsimi Baqsimi Growth | - | - | 29.1 | 677.6 | 139.3 | 113.2 |
Basaglar Basaglar Growth | 658.2 | 626 | 676.9 | 728.3 | 760.4 | 892.5 |
Humalog Humalog Growth | 2,073 | 2,168 | 2,325 | 1,663 | 2,061 | 2,453 |
Humulin Humulin Growth | 691.8 | 705 | 917.1 | 852.1 | 1,019 | 1,223 |
Jardiance Jardiance Growth | 3,531 | 3,432 | 3,341 | 2,745 | 2,066 | 1,491 |
Mounjaro Mounjaro Growth | 27,785 | 22,965 | 11,540 | 5,163 | 482.5 | - |
Trajenta Trajenta Growth | 318.1 | 318 | 353.9 | 386.9 | 383.7 | 372.5 |
Trulicity Trulicity Growth | 4,100 | 4,276 | 5,254 | 7,133 | 7,440 | 6,472 |
Zepbound Zepbound Growth | 15,391 | 13,542 | 4,926 | 175.8 | - | - |
Other Cardiometabolic Health Other Cardiometabolic Health Growth | 225.9 | 189 | 187.9 | 143.1 | 80.8 | 121.2 |
Oncology Oncology Growth | 9,696 | 9,376 | 8,752 | 6,658 | 5,666 | 5,741 |
Immunology Immunology Growth | 5,362 | 5,247 | 4,393 | 3,798 | 3,345 | 3,361 |
Neuroscience Neuroscience Growth | 1,502 | 1,391 | 1,473 | 2,879 | 1,546 | 1,899 |
Other Product Other Product Growth | 917.7 | 944 | 903 | 1,122 | 3,520 | 4,130 |
Revenue (Total) Revenue (Total) Growth | 72,250 | 65,179 | 45,043 | 34,124 | 28,541 | 28,318 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 5,282 | 7,268 | 3,268 | 2,928 | 2,212 | 3,909 |
Total Debt Total Debt Growth | 43,370 | 42,503 | 33,644 | 25,225 | 16,239 | 16,885 |
Net Cash (Debt) Net Cash Growth | -38,088 | -35,235 | -30,376 | -22,298 | -14,027 | -12,976 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -42.41 | -39.18 | -33.60 | -24.68 | -15.51 | -14.23 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 20,480 | 16,813 | 8,818 | 4,240 | 7,586 | 7,366 |
Capital Expenditures CapEx Growth | -8,657 | -7,841 | -5,058 | -3,448 | -1,854 | -1,310 |
Free Cash Flow Free Cash Flow Growth | 11,823 | 8,972 | 3,760 | 792 | 5,731 | 6,056 |
Free Cash Flow Growth | 216.44% | 138.62% | 374.75% | -86.18% | -5.36% | 18.48% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 82.83% | 83.04% | 81.31% | 79.25% | 76.77% | 74.18% |
Operating Margin | 43.63% | 40.35% | 28.64% | 18.92% | 24.97% | 22.45% |
Pretax Margin | 43.08% | 39.48% | 28.15% | 19.21% | 23.85% | 21.74% |
Profit Margin | 34.99% | 31.67% | 23.51% | 15.36% | 21.88% | 19.71% |
FCF Margin | 16.36% | 13.77% | 8.35% | 2.32% | 20.08% | 21.39% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 6.920 | 6.000 | 5.200 | 4.520 | 3.920 | 3.400 |
Dividend Per Share Growth | 15.34% | 15.38% | 15.04% | 15.31% | 15.29% | 14.87% |
Dividend Yield | 0.60% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 40.81 | 46.83 | 65.93 | 100.50 | 53.02 | 45.13 |
Forward PE | 32.16 | 34.33 | 35.13 | 53.37 | 46.27 | 31.77 |
P/FCF Ratio | 86.65 | 107.18 | 184.28 | 661.95 | 57.46 | 41.22 |
PS Ratio | 14.18 | 14.75 | 15.38 | 15.36 | 11.54 | 8.81 |